ArticleOncology letters2017
Lumican expression in gastric cancer and its association with biological behavior and prognosis.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Representing ECM composition and EMT pathways in gastric cancer using a new metastatic gene signature.Frontiers in cell and developmental biology · 2024Article
- Research Progress on Extracellular Matrix Involved in the Development of Preeclampsia.Current protein & peptide science · 2024Review
- The Landscape of Small Leucine-Rich Proteoglycan Impact on Cancer Pathogenesis with a Focus on Biglycan and Lumican.Cancers · 2023Review
- Small leucine rich proteoglycans: Biology, function and their therapeutic potential in the ocular surface.The ocular surface · 2023Review
- Pirin is a prognostic marker of human melanoma that dampens the proliferation of malignant cells by downregulating JARID1B/KDM5B expression.Scientific reports · 2023Article
- Multi-omics analysis reveals the prognostic and tumor micro-environmental value of lumican in multiple cancer types.Frontiers in molecular biosciences · 2023Article
- Differential MMP-14 Targeting by Lumican-Derived Peptides Unraveled by In Silico Approach.Cancers · 2021Article
- Lumican in Carcinogenesis-Revisited.Biomolecules · 2021Review
- Effects ofExperimental and therapeutic medicine · 2021Article
- Epiphycan Predicts Poor Outcomes and Promotes Metastasis in Ovarian Cancer.Frontiers in oncology · 2021Article
- Lumican mediates HTB94 chondrosarcoma cell growth via an IGF‑IR/Erk1/2 axis.International journal of oncology · 2020Article
- LUM Expression and Its Prognostic Significance in Gastric Cancer.Frontiers in oncology · 2020Article
- Article
- Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.Journal of Cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the expression of lumican in human gastric cancer and adjacent normal gastric tissues, and study its association with clinicopathological characteristics and survival rate. By using immunohistochemistry, the lumican expression patterns in 146 cases of gastric cancer with various clinicopathological characteristics 55 adjacent normal gastric tissue specimens was studied. And the significance of lumican expression regarding the biological behavior and survival of patients was evaluated. In adjacent normal gastric tissues, lumican was expressed weakly in 10.9% (6/55) of samples. By contrast, the lumican expression rate was 66.4% (97/146) in gastric cancer tissues. Lumican protein expression was closely associated with organ metastasis, lymphatic metastasis and histological type (P<0.05), but not with the tumor location, size, invasion depth or Borrmann type (P>0.05). The median survival time in patients with negative, weakly positive and strongly positive lumican expression was 46.3, 39.6 and 24.3 months, respectively (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.